Literature DB >> 26388507

Messenger RNA expression profile of sleep-related genes in peripheral blood cells in patients with chronic kidney disease.

Shinji Kitajima1, Yasunori Iwata2,3,4,5, Kengo Furuichi2,3,4,5, Akihiro Sagara2,3,4,5, Yasuyuki Shinozaki2,3,4,5, Tadashi Toyama2,3,4,5, Norihiko Sakai2,3,4,5, Miho Shimizu2,3,4,5, Takeshi Sakurai2,3,4,5, Shuichi Kaneko2,3,4,5, Takashi Wada2,3,4,5.   

Abstract

BACKGROUND: Various sleep abnormalities, such as delayed sleep onset, frequent awakening and daytime sleepiness, deteriorate the quality of life in patients with chronic kidney disease (CKD), including those on haemodialysis (HD). Although there are some candidate causative molecules in the central nervous system, the contribution of peripheral blood cells (PBCs) remains unclear. In this study, we performed polysomnographic analysis in CKD patients and used PBCs to examine the expression of genes related to sleep and wakefulness states.
METHODS: Polysomnographic analysis was performed in 9 CKD patients and 6 controls. Genes related to sleep and wakefulness were evaluated by RNA microarray in 19 subjects, including CKD patients and control subjects.
RESULTS: Polysomnographic analysis revealed that the duration of the rapid eye movement (REM)/non-REM phases during total sleep time was different between CKD patients and healthy controls. In mRNA microarray evaluation, hierarchical clustering analysis showed different patterns of sleep-related gene expression in HD patients. mRNA expression levels of GABA receptor (GABBR2), noradrenaline receptor (ADRA1A), dopamine receptor (DRD1) and histamine receptor (HRH1) showed an inverse correlation with renal function. Moreover, the mRNA expression of orexin and its receptor (HCRTR1 and HCRTR2) was also inversely correlated with renal function.
CONCLUSION: These data indicate that the expression of sleep-related genes in PBCs of CKD patients may be associated with sleep abnormalities.

Entities:  

Keywords:  CKD; Gene expression; Orexin; Sleep abnormalities

Mesh:

Substances:

Year:  2015        PMID: 26388507     DOI: 10.1007/s10157-015-1150-y

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  26 in total

1.  Polysomnographic measures of nocturnal sleep in patients on chronic, intermittent daytime haemodialysis vs those with chronic kidney disease.

Authors:  Kathy P Parker; Donald L Bliwise; James L Bailey; David B Rye
Journal:  Nephrol Dial Transplant       Date:  2005-04-19       Impact factor: 5.992

2.  Functional status and quality of life: predictors of early mortality among patients entering treatment for end stage renal disease.

Authors:  W M McClellan; C Anson; K Birkeli; E Tuttle
Journal:  J Clin Epidemiol       Date:  1991       Impact factor: 6.437

3.  A putative flip-flop switch for control of REM sleep.

Authors:  Jun Lu; David Sherman; Marshall Devor; Clifford B Saper
Journal:  Nature       Date:  2006-05-10       Impact factor: 49.962

Review 4.  REM sleep loss increases brain excitability: role of noradrenaline and its mechanism of action.

Authors:  Birendra N Mallick; Abhishek Singh
Journal:  Sleep Med Rev       Date:  2011-04-08       Impact factor: 11.609

5.  Correlates of sleep behavior among hemodialysis patients. The kidney outcomes prediction and evaluation (KOPE) study.

Authors:  Sharon Wallace Williams; Grethe S Tell; Beiyao Zheng; Sally Shumaker; Michael V Rocco; Mary Ann Sevick
Journal:  Am J Nephrol       Date:  2002 Jan-Feb       Impact factor: 3.754

6.  Sleep in untreated patients with schizophrenia: a meta-analysis.

Authors:  Sylvie Chouinard; Julie Poulin; Emmanuel Stip; Roger Godbout
Journal:  Schizophr Bull       Date:  2004       Impact factor: 9.306

7.  Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.

Authors:  T Sakurai; A Amemiya; M Ishii; I Matsuzaki; R M Chemelli; H Tanaka; S C Williams; J A Richardson; G P Kozlowski; S Wilson; J R Arch; R E Buckingham; A C Haynes; S A Carr; R S Annan; D E McNulty; W S Liu; J A Terrett; N A Elshourbagy; D J Bergsma; M Yanagisawa
Journal:  Cell       Date:  1998-02-20       Impact factor: 41.582

8.  Significant differences in gene expression of GABA receptors in peripheral blood leukocytes of migraineurs.

Authors:  Prue N Plummer; Natalie J Colson; Joanne M Lewohl; Rachel K MacKay; Francesca Fernandez; Larisa M Haupt; Lyn R Griffiths
Journal:  Gene       Date:  2011-09-24       Impact factor: 3.688

9.  Comparison of sleep quality between hemodialysis and peritoneal dialysis patients.

Authors:  Nazmiye Eryavuz; Seref Yuksel; Gursel Acarturk; Ihsan Uslan; Serap Demir; Murat Demir; M Tugrul Sezer
Journal:  Int Urol Nephrol       Date:  2008-04-22       Impact factor: 2.370

10.  A comparison of reported sleep disorders in patients on chronic hemodialysis and continuous peritoneal dialysis.

Authors:  J L Holley; S Nespor; R Rault
Journal:  Am J Kidney Dis       Date:  1992-02       Impact factor: 8.860

View more
  4 in total

1.  A comparison of gene expression profiles in patients with coronary artery disease, type 2 diabetes, and their coexisting conditions.

Authors:  Rui Gong; Menghui Chen; Cuizhao Zhang; Manli Chen; Haibin Li
Journal:  Diagn Pathol       Date:  2017-06-08       Impact factor: 2.644

2.  Co-Expression Analysis of Blood Cell Genome Expression to Preliminary Investigation of Regulatory Mechanisms in Uremia.

Authors:  Liu Cheng; Wu Yonggui
Journal:  Med Sci Monit       Date:  2017-01-04

Review 3.  Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.

Authors:  Raymond Vanholder; Anneleen Pletinck; Eva Schepers; Griet Glorieux
Journal:  Toxins (Basel)       Date:  2018-01-08       Impact factor: 4.546

4.  Indoxyl Sulfate-Mediated Metabolic Alteration of Transcriptome Signatures in Monocytes of Patients with End-Stage Renal Disease (ESRD).

Authors:  Hee Young Kim; Su Jeong Lee; Yuri Hwang; Ga Hye Lee; Chae Eun Yoon; Hyeon Chang Kim; Tae-Hyun Yoo; Won-Woo Lee
Journal:  Toxins (Basel)       Date:  2020-09-28       Impact factor: 4.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.